MedPath

Demonstrating Pemetrexed induced Thymidylate Synthase inhibition in non-small cell lung cancer in vivo: a pilot study.

Recruiting
Conditions
NSCLC
10038666
Registration Number
NL-OMON32208
Lead Sponsor
Vrije Universiteit Medisch Centrum
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
12
Inclusion Criteria

Patient age 18 years or older
Histological diagnosis of NSCLC
Scheduled for treatment with pemetrexed
Tumour diameter min. 3cm (to minimize partial volume effects) within the chest
Able to remain supine for 60 minutes
Written informed consent

Exclusion Criteria

Pregnant or lactating patients
Claustrophobia
Patients having metal implants (e.g. pacemakers)

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Change of 18F-FLT uptake as measured with time lapse of 4 hrs after pemetrexed.<br /><br>18F-FLT changes versus clinical response measured with RECIST.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Not applicable</p><br>
© Copyright 2025. All Rights Reserved by MedPath